2. Anti-infection
  3. HBV
  4. HBV-IN-56

HBV-IN-56 is an orally active HBsAg production inhibitor. HBV-IN-56 inhibits HBsAg production both in vitro and in vivo. HBV-IN-56 can be used for the research of chronic hepatitis B virus infection.

For research use only. We do not sell to patients.

HBV-IN-56

HBV-IN-56 Chemical Structure

CAS No. : 2564693-71-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

HBV-IN-56 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

HBV-IN-56 is an orally active HBsAg production inhibitor. HBV-IN-56 inhibits HBsAg production both in vitro and in vivo. HBV-IN-56 can be used for the research of chronic hepatitis B virus infection[1].

In Vitro

HBV-IN-56 (compound 31) potently inhibits HBsAg production in HBV-infected primary human hepatocytes, with an IC50 of 5 nM, and shows no cytotoxicity at concentrations up to 15,000 nM[1].
HBV-IN-56 (10-50 μM) exhibits extremely low off-target activity in safety assessment assays, including no significant kinase inhibition, CYP inhibition, hERG channel activity, or genotoxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HBV-IN-56 Related Antibodies
Parmacokinetics
Species Dose Route CL Vss T1/2 Bioavailability
Mice[1] 0.1 mg/kg i.v. 0.222 L/h/kg 2.4 L/kg 1.90 h /
Mice[1] 5 mg/kg p.o. / / 4.31 h 49 %
Rat[1] 0.1 mg/kg i.v. 0.08 L/h/kg 0.506 L/kg 4.47 h /
Rat[1] 10 mg/kg p.o. / / 9.10 h 97 %
Dog[1] 1 mg/kg i.v. 0.045 L/h/kg 0.485 L/kg 7.79 h /
Dog[1] 5 mg/kg p.o. / / 9.11 h 86 %
In Vivo

HBV-IN-56 (compound 31) (0.1-1 mg/kg; p.o.; 21 days) reduces and sustains serum HBsAg levels in HBV-infected humanized FRG mice[1].
HBV-IN-56 (3-60 mg/kg; p.o.; 91 days) induces dose- and duration-dependent decreases in tail NCV and axonopathy in Sprague-Dawley rats, with no recovery observed 4 weeks after the end of administration[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male and female; 10 weeks old at study initiation, males 357-474 g, females 262-330 g)[1]
Dosage: 3 mg/kg; 10 mg/kg; 30 mg/kg; 60 mg/kg
Administration: p.o.; daily; 91 days
Result: Reduced caudal nerve conduction velocity (NCV) over the 13-week treatment period, with effects correlated to both dose and treatment duration.
Showed no recovery in caudal NCV in any dose group during the 4-week post-treatment recovery period and detected axonopathy via histological analysis at all dose levels.
Molecular Weight

437.89

Formula

C20H20ClNO6S
CAS No.
SMILES

ClC1=CC(C2=C(C3)C=C(C(N2C4CC4)=O)C(O)=O)=C(C=C1OCC(C)C)S3(=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

HBV-IN-56 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HBV-IN-562564693-71-4HBVHepatitis B virushumanized FRG micerat embryonic primary sensory neuronsprimary human hepatocyteshERG channelHBsAgMDCK-MDR1 cellshepatitis B virusInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
HBV-IN-56
Cat. No.:
HY-181348
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.